1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Genital Herpes - Pipeline Review, H1 2016

Genital Herpes - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 101 pages

Genital Herpes - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Genital Herpes - Pipeline Review, H1 2016’, provides an overview of the Genital Herpes pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Genital Herpes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Genital Herpes
- The report reviews pipeline therapeutics for Genital Herpes by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Genital Herpes therapeutics and enlists all their major and minor projects
- The report assesses Genital Herpes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Genital Herpes

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Genital Herpes
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Genital Herpes - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Genital Herpes Overview 9
Therapeutics Development 10
Pipeline Products for Genital Herpes - Overview 10
Pipeline Products for Genital Herpes - Comparative Analysis 11
Genital Herpes - Therapeutics under Development by Companies 12
Genital Herpes - Therapeutics under Investigation by Universities/Institutes 14
Genital Herpes - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Genital Herpes - Products under Development by Companies 17
Genital Herpes - Products under Investigation by Universities/Institutes 18
Genital Herpes - Companies Involved in Therapeutics Development 19
Admedus Ltd 19
AiCuris GmbH and Co. KG 20
Foamix Pharmaceuticals Ltd. 21
Genocea Biosciences, Inc. 22
GenVec, Inc. 23
Immune Design Corp. 24
Immunovaccine, Inc. 25
Mymetics Corporation 26
NanoBio Corporation 27
NanoViricides, Inc. 28
PaxVax, Inc. 29
Profectus BioSciences, Inc. 30
Sanofi Pasteur SA 31
Shulov Innovative Science Ltd. 32
Starpharma Holdings Limited 33
Vaccibody AS 34
Vaxart, Inc. 35
Vical Incorporated 36
Genital Herpes - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
acyclovir - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Aspidasept - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
astodrimer - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
G-103 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
GEN-002 - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
GEN-003 - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
genital herpes vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
GV-2207 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Herpecide - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
herpes simplex virus [type 1, 2] vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
herpes simplex virus [type 1, 2] vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
herpes simplex virus 2 vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
herpes simplex virus 2 vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
herpes simplex virus 2 vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
herpes simplex virus 2 vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
herpes simplex virus 2 vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
herpes simplex virus 2 vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
herpes simplex virus 2 vaccine - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
herpes simplex virus 2 vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
herpes simplex virus 2 vaccine - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
HSV-529 - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
pritelivir - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
VCLHB-01 - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
VCLHM-01 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
ZEP-3 - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
Genital Herpes - Recent Pipeline Updates 77
Genital Herpes - Dormant Projects 89
Genital Herpes - Discontinued Products 91
Genital Herpes - Product Development Milestones 92
Featured News and Press Releases 92
Feb 03, 2016: Model helps decide drug dose for clinical testing 92
Jan 29, 2016: Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003 92
Oct 07, 2015: Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003 93
Sep 22, 2015: NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine 94
Aug 17, 2015: NanoViricides Accelerates its Herpes Drug Development Program 95
Aug 17, 2015: Vaxart to Present at the 6th Euro Global Summit and Expo on Vaccines and Vaccination in Birmingham, UK on August 18, 2015 96
May 20, 2015: Genocea Announces Positive Top-Line Phase 2 Data for Genital Herpes Immunotherapy GEN-003 96
Apr 10, 2015: Admedus has high hopes for Herpes vaccine as dosing commences 97
Jan 07, 2015: Genocea Completes Enrollment Early in Phase 2 Dose Optimization Trial of GEN-003 for Treatment of Genital Herpes 98
Oct 08, 2014: NanoBio To Present Data Demonstrating The Potential For Its Intranasal Vaccine To Protect Against Genital Herpes Infection 98
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 100
Disclaimer 101

List of Tables
Number of Products under Development for Genital Herpes, H1 2016 10
Number of Products under Development for Genital Herpes - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Genital Herpes - Pipeline by Admedus Ltd, H1 2016 19
Genital Herpes - Pipeline by AiCuris GmbH and Co. KG, H1 2016 20
Genital Herpes - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 21
Genital Herpes - Pipeline by Genocea Biosciences, Inc., H1 2016 22
Genital Herpes - Pipeline by GenVec, Inc., H1 2016 23
Genital Herpes - Pipeline by Immune Design Corp., H1 2016 24
Genital Herpes - Pipeline by Immunovaccine, Inc., H1 2016 25
Genital Herpes - Pipeline by Mymetics Corporation, H1 2016 26
Genital Herpes - Pipeline by NanoBio Corporation, H1 2016 27
Genital Herpes - Pipeline by NanoViricides, Inc., H1 2016 28
Genital Herpes - Pipeline by PaxVax, Inc., H1 2016 29
Genital Herpes - Pipeline by Profectus BioSciences, Inc., H1 2016 30
Genital Herpes - Pipeline by Sanofi Pasteur SA, H1 2016 31
Genital Herpes - Pipeline by Shulov Innovative Science Ltd., H1 2016 32
Genital Herpes - Pipeline by Starpharma Holdings Limited, H1 2016 33
Genital Herpes - Pipeline by Vaccibody AS, H1 2016 34
Genital Herpes - Pipeline by Vaxart, Inc., H1 2016 35
Genital Herpes - Pipeline by Vical Incorporated, H1 2016 36
Assessment by Monotherapy Products, H1 2016 37
Number of Products by Stage and Target, H1 2016 39
Number of Products by Stage and Mechanism of Action, H1 2016 41
Number of Products by Stage and Route of Administration, H1 2016 43
Number of Products by Stage and Molecule Type, H1 2016 45
Genital Herpes Therapeutics - Recent Pipeline Updates, H1 2016 77
Genital Herpes - Dormant Projects, H1 2016 89
Genital Herpes - Dormant Projects (Contd..1), H1 2016 90
Genital Herpes - Discontinued Products, H1 2016 91

List of Figures
Number of Products under Development for Genital Herpes, H1 2016 10
Number of Products under Development for Genital Herpes - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Products, H1 2016 16
Assessment by Monotherapy Products, H1 2016 37
Number of Products by Targets, H1 2016 38
Number of Products by Stage and Targets, H1 2016 38
Number of Products by Mechanism of Actions, H1 2016 40
Number of Products by Stage and Mechanism of Actions, H1 2016 40
Number of Products by Routes of Administration, H1 2016 42
Number of Products by Stage and Routes of Administration, H1 2016 42
Number of Products by Molecule Types, H1 2016 44
Number of Products by Stage and Molecule Types, H1 2016 44

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: Kol Insight

September 2016 $ 8085

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy Market in Europe

  • November 2016
    19 pages
  • Therapy  

  • Europe  

View report >

Therapy Market and Hypertension Statistics in Asia and the US

  • November 2016
    26 pages
  • Therapy  

    Hypertension  

    Cardiovascular ...  

  • Asia  

    United States  

    Europe  

View report >

Therapy Market in the US - Forecast

  • November 2016
    6 pages
  • Therapy  

    Opioid  

  • United States  

View report >

Related Market Segments :

Therapy
Vaccine
Pharmaceutical
Infectious Disease

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.